Reapplix Is A Danish Medtech Company Founded In 2008Specializing In The Biological Treatment And Management Of Diabetic Foot Ulcersheadquartered In Birkeroddenmarkthe Company Has Sales And Distribution Teams In The Us And Europeits Core Productthe 3C Patch Systemis An Evidence Based Biological Wound Therapy That Uses Components From The Patient S Own Blood To Promote Healingthis Innovative Treatment Is Applied Directly To The Wound At Point Of Careharnessing The Body S Natural Healing Abilities The Effectiveness Of The 3C Patch System Is Supported By Clinical Studies Published In Reputable Medical Journalshighlighting Its Potential In Transforming Diabetic Foot Ulcer Managementreapplix Has Established Favorable Reimbursement Conditions In The Us And Has Received An Innovative Technology Contract From Vizientenhancing Its Commercial Rolloutthe Company Has Also Secured Investment From Lauxera Capital Partners To Support Its Growthkira Rupprecht Serves As The Ceoleading Reapplix As It Continues To Innovate In Wound Care
No conferences found for this company.
| Company Name | Reapplix Inc |
| Country |
Denmark
|
| Address | N/A |
| Telephone | N/A |
| N/A |
